Article Text


IL-7-activated T cells and monocytes drive B cell activation in patients with primary Sjögren's syndrome
  1. A Bikker,
  2. KMG van der Wurff-Jacobs,
  3. AA Kruize,
  4. RP Peters,
  5. JWJ Bijlsma,
  6. FPJG Lafeber,
  7. JAG van Roon
  1. UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands; a.bikker{at}


In primary Sjögren's syndrome (pSS) patients local T and B cell-driven inflammation can contribute to destruction of exocrine glands associated with clinical symptoms of dryness. Recently we documented increased interleukin 7 (IL-7) and IL7R expression in labial salivary glands of pSS patients. We have shown that IL-7 causes T cell-dependent monocyte activation. Although there are indications that IL-7 affects the activity of developing human B cells, the effect of IL-7 on mature B cell activation in human autoimmune diseases has not been reported. Because B cell activation plays a pivotal role in pSS pathology we investigated the capacity of IL-7 to induce T cell-dependent B cell activation.

Peripheral blood mononuclear cells (PBMCs) from pSS patients (n=6) were cultured with and without IL-7. Furthermore, isolated CD4 T and CD19 B cells were co-cultured with and without IL-7 as well, and in the presence or absence of CD14 monocytes/macrophages (n=6). Proliferation was measured using 3H-thymidine incorporation and by Ki67 expression (FACS analysis). Ex vivo IL-7R expression and activation marker expression (HLA-DR, CD25) on CD4 T and B cells were measured by FACS analysis.

Nearly all CD4 T cells express the IL-7R (93.6 ±1.4%), while B 3cells and monocytes do not. IL-7 increased proliferation of PBMC pSS (from 2000 to 13000 cpm, p≤0.001), which was associated with significant increases in Ki67+CD4 T cells (from 2.7 ±0.4% to 13.8 ±4.0%) and Ki67+B cells (from 1.5 ±0.2% to 3.4 ±0.5%). Additionally, IL-7 up regulated markers of activation on CD4 T cells (CD25+ CD4 T cells from 28.8 ±4.0% to 79.8 ±2.4%, p≤0.001; HLA-DR+ T cells from 7.1 ±0.4% to 8.9 ±0.7%, p≤0.05), and on B cells (HLA-DR MFI from 317 ±109 to 421 ±129, p<0.01; mean increase 33%). In CD4 T and B cell co-cultures, IL-7 activated T cells, but caused minimal B cell activation (MFI HLA-DR from 214 ±32 to 233 ±30, p≤0.05; mean increase 8.8%). As it has been shown that monocytes are able to support B cell activation and can be stimulated by IL7-activated CD4 T cells, the capacity of monocytes to facilitate IL-7-induced B cell activation was examined. We report that indeed IL-7-induced T cell activation of B cells is significantly enhanced by monocytes (MFI HLA-DR on B cells from 210 ±32 to 284 ±53, p≤0.05; mean increase 35%).

Our results show that IL-7 activates B cells in a T cell-dependent manner which is facilitated by monocytes. Since increased IL-7 levels and monocyte/macrophage numbers are associated with increased immunopathology in pSS this suggests that IL-7-driven B cell activation might contribute to inflammation and tissue-destruction in pSS.

Statistics from


  • Funding This study was financially supported by the Dutch Arthritis Association (‘het Nationaal Reumafonds’).

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.